gooブログはじめました!

写真付きで日記や趣味を書くならgooブログ

Experts gather to discuss the efficient creation and delivery ofnanoscale particles of drugs

2013-09-06 12:41:04 | 日記
From targeted cancer chemotherapy to the guarantee of successful organ transplants, the21st century may prove to be the age of big ideas in medicine. The drugs themselves, though, will be minuscule. Experts in chemistry, applied physics, materials science, andpharmaceutical science gathered this week for the BASF AdvancedResearch Initiative at Harvard University's symposium onpharmaceutical nanoformulations. The two-day symposium, co-hosted by the Harvard School ofEngineering and Applied Sciences (SEAS) and leading chemicalcompany BASF, and held at the American Academy of Arts and Sciencesin Cambridge, provided an opportunity for more than 200 leadingresearchers to discuss the challenges of modern medicine and thesearch for innovative solutions in nanotechnology.

Small particles with big potential A great deal of research in engineering and the applied sciencestoday involves the manipulation of materials at the nanometer scaleto achieve particular physical and chemical properties. In the realm of pharmacy science, for instance, many recentlydeveloped drug compounds are strongly hydrophobic, meaning thattheir molecules do not dissolve easily in water - or, therefore, inthe bloodstream. "That problem can be overcome if the drug particles are tinyenough, on the order of a few billionths of a meter," says DavidWeitz, Mallinckrodt Professor of Physics and Applied Physics atSEAS and co-director of the BASF Advanced Research Initiative. The grand challenge in the field of nanoformulations involves boththe creation of precisely tailored, nanoscale particles of drugsand the safe and efficient delivery of those tiny particles totheir exact targets within the human body. BASF supports researchers at SEAS and across Harvard who areexploring a variety of approaches to this problem.

"I have a vision that is inspired in part by the fact that mostpeople say it's impossible," says Weitz. "I think we can makemeaningful quantities of valuable materials using microfluidics asa fabrication strategy. There are people at BASF who believe inthat, and they've been supporting work in my lab." At the symposium, he says, "I'll try to convince people that yes,we can." Attendees will also hear from George Whitesides, Woodford L. andAnn A. Pet Carrier Bags

Flowers University Professor at Harvard; and David Mooney,Robert P. Pinkas Family Professor of Bioengineering at SEAS.(Whitesides and Mooney are also core faculty members at the WyssInstitute for Biologically Inspired Engineering at Harvard.) At SEAS, Mooney has been working to develop a therapeutic cancervaccine that enhances the body's immune response by using novelbiomaterials and nanoparticles to deliver signals to the cells thatinitiate adaptive immunity. (The full list of speakers is available here .) Joining competencies: Industry meets academia The BASF Advanced Research Initiative at Harvard Universityrepresents a powerful model for university-industry collaboration,providing direct funding to faculty, graduate students, andresearchers at SEAS and across the University. Created in October2007, the initiative fosters a vibrant and dynamic intellectualexchange and accelerates the adoption of significant newtechnologies. Recycled PET Bag

"Innovations succeed best of all in collaboration with goodpartners," says Jens Rieger, Senior Vice President, PolymerResearch Division, BASF SE, and co-director of the BASF AdvancedResearch Initiative at Harvard. "Our research cooperation withHarvard has not only strengthened our research network in theUnited States, but provided an optimum basis for collectivelyharnessing the innovative potential of new technologies to confrontglobal challenges. Together we have demonstrated that we haveformed the right team to find sustainable solutions for enhancedquality of life." BASF supports research in nine different laboratories at Harvard,involving work in materials science, applied mathematics, appliedphysics, bioengineering, molecular and cellular biology,microbiology and immunobiology, and chemistry and chemical biology.Nanopharmaceuticals represent one thrust of the research; the otherinvolves preventing or removing biofilms - a type of bacterialgrowth that can cause serious diseases in humans and are a majorconcern in industrial processes and water management. BASF has provided Harvard with direct funding since 2007,supporting the careers of 22 graduate students and 32 postdoctoralresearchers. The collaboration has led to a number of patents andpublications. Recycled Shopping Bags

"The partnership works because BASF is an organization that bringsus really intellectually challenging problems, that incorporatesour results into its business, that learns from us, and thatsupports our research," says Weitz. "The value to them, in turn, isthat we bring people who are a little bit removed from theday-to-day pressures of their business, but who can work togetherconstructively to tackle difficult problems in a multidisciplinaryway. "This has become a model for interactions between industry andacademia," Weitz adds. Additional References Citations.

Single injection allows relief from pain for 8 months followingspinal cord injury

2013-09-06 12:35:32 | 旅行
A collaborative research group - led by researchers at ClevelandClinic - published findings that indicate a one-time injectionimmediately after spinal cord injury can limit pain for an extendedperiod of time. Fibronectin - a protein that exists naturally in humans - supportsthe survival, growth and communication of neurons in the brain andspinal cord. The researchers discovered, through testing in ananimal model, that an injection of fibronectin into the spinal cordactivates specific signaling pathways and results in pain-curbingeffects. "We are very pleased with the results from the fibronectininjection," said Ching-Yi Lin, Ph.D., a researcher in theDepartment of Neurosciences in Cleveland Clinic's Lerner ResearchInstitute. "Perhaps this will signal a change in pain managementafter spinal cord injury." Previous research has shown that spinal cord injury increases thepermeability of the blood-spinal cord barrier, causing chronic paindue to exposure of the spinal cord to inflammatory cells. In Dash Car DVD Player

Pain is aparticularly important problem after spinal cord injury since thetype of pain that ensues after a spinal cord injury is consideredeven more debilitating than the paralysis itself. The findings were published in the December issue of the Journal of Neurotrauma and were presented at the annual meeting of Society ofNeuroscience. This is a collaborative project between Lin andYu-Shang Lee, Ph.D., both of the Department of Neurosciences inCleveland Clinic's Lerner Research Institute; Vernon Lin, M.D.,Ph.D., Department of Physical Medicine and Rehabilitation,Cleveland Clinic; and Jerry Silver, Ph.D., Department ofNeurosciences, Case Western Reserve University. While the exact mechanisms underlying the possible fibronectinconnection to the relief of chronic pain are not clear yet, resultsshow that fibronectin not only maintained the integrity of theblood-spinal cord barrier but also suppressed the inflammatoryresponse significantly over an eight-month period. Researchersfound that fibronectin reversed spinal cord injury-induceddecreases in serotonin, a neurotransmitter that plays an importantrole in pain perception. Ford DVD Navigation System Manufacturer

The next stage of the study is to test the delayed fibronectintreatment on the inhibition of chronic pain after spinal cordinjury, which is more clinically relevant. There is an indicationthat this treatment also works at later time points. Additional References Citations. Suzuki DVD GPS